top of page


Arvo Logo Red Blue.jpg

GelMEDIX to Present at ARVO and OIS Retina 2024

While current retinal cell therapies leveraging retinal pigment epithelial (RPE) cells are promising, they suffer from process limitations that lead to high adverse event rates (i.e. retinal membrane formation, retinal detachment/hemorrhage) that make them unable to improve patient vision at scale.


GelMEDIX is excited to present never-before-seen data on novel approaches to RPE regeneration at the upcoming ARVO and OIS Retina conferences in Seattle. We'll share how in situ formed hydrogel scaffolds optimize RPE engraftment leading to an 8X increase in cell localization and improved cell morphology post-transplantation in porcine, as well as never-before shared data demonstrating RPE monolayer restoration in a rabbit model of GA.


Join us at OIS on Saturday or hear from our R&D team on Monday morning at ARVO (B0312) to delve into this topic.


We look forward to a productive week focused on vision research as we continue to work toward restoring vision for patients.

Scientist Pipetting

MARCH 10, 2022

HTL Announces Its Incubator's Equity Investment In GelMEDIX, An Early-Stage Biotech Aiming At Revolutionizing Ocular And Regenerative Therapies

AbbVie Golden Ticket Winner 2021

bottom of page